TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04864834

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SOK583A1 (40 mg/mL)
Description: IVT administration of 2 mg of SOK583A1 in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Eylea EU (40 mg/mL)
Description: IVT administration of 2 mg of Eylea EU in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.
Study: NCT04955574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SH-DS01 + Antibiotic Placebo
Description: Participants will be instructed to take 2 capsules of SH-DS01 probiotic once daily (at lunch) from cycle day 1 to the day of ovulation/day of luteal progesterone initiation, followed by 2 capsules of SH-DS01 probiotic once daily (at lunch) and 1 capsule of placebo for antibiotic twice daily (at breakfast and dinner) from the day of ovulation/day of luteal progesterone initiation to the day of frozen embryo transfer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH-DS01 + Metronidazole
Description: Participants will be instructed to take 2 capsules of SH-DS01 probiotic once daily (at lunch) from cycle day 1 to the day of ovulation/day of luteal progesterone initiation, followed by 2 capsules of SH-DS01 probiotic once daily (at lunch) and 1 capsule of 500mg metronidazole twice daily (at breakfast and dinner) from the day of ovulation/day of luteal progesterone initiation to the day of frozen embryo transfer.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic Placebo + Antibiotic Placebo
Description: Participants will be instructed to take 2 capsules of placebo for probiotic once daily (at lunch) from cycle day 1 to the day of ovulation/day of luteal progesterone initiation, followed by 2 capsules of placebo for probiotic once daily (at lunch) and 1 capsule of placebo for antibiotic twice daily (at breakfast and dinner) from the day of ovulation/day of luteal progesterone initiation to the day of frozen embryo transfer.
Study: NCT05864391

Intervention type: DRUG
Group type: OTHER
Intervention: AZD7503
Description: Each participant is expected to be in the study for approximately 24 weeks, including a screening period of up to 28 days, a 12-week study intervention period, and a follow-up visit at week 18 (10 weeks following the final dose). Participants will be randomly assigned in a 3:1 ratio to receive AZD7503 or placebo. Study intervention will be administered via subcutaneous injection.

Intervention type: DRUG
Group type: OTHER
Intervention: AZD7503
Description: Each participant is expected to be in the study for approximately 24 weeks, including a screening period of up to 28 days, a 12-week study intervention period, and a follow-up visit at week 18 (10 weeks following the final dose). Participants will be randomly assigned in a 3:1 ratio to receive AZD7503 or placebo. Study intervention will be administered via subcutaneous injection.

Intervention type: DRUG
Group type: OTHER
Intervention: AZD7503
Description: Each participant is expected to be in the study for approximately 24 weeks, including a screening period of up to 28 days, a 12-week study intervention period, and a follow-up visit at week 18 (10 weeks following the final dose). Participants will be randomly assigned in a 3:1 ratio to receive AZD7503 or placebo. Study intervention will be administered via subcutaneous injection.
Study: NCT05728151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Articaine and Epinephrine Only Product
Description: comparison between its effect with the other two local anesthetic drugs in peribulbar block on oculocardiac reflex intraoperatively and postoperative pain in pediatrics undergoing squint surgeries with general anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levobupivacaine
Description: comparison between its effect with the other two local anesthetic drugs in peribulbar block on oculocardiac reflex intraoperatively and postoperative pain in pediatrics undergoing squint surgeries with general anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mepivacaine
Description: comparison between its effect with the other two local anesthetic drugs in peribulbar block on oculocardiac reflex intraoperatively and in peribulbar block on postoperative pain in pediatrics undergoing squint surgeries with general anesthesia
Study: NCT04961645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: TMS is a safe and noninvasive method for affecting brain function relying on the properties of electromagnetic induction. Action potentials are triggered in neurons, along with a subsequent period of deactivation. Normal ongoing brain activity is disrupted providing a way for investigators to produce a transient and reversible period of brain disruption.~Participants will be seated comfortably in a chair and asked to complete either a simple computer-based task or a simple behavioral task that will require them to walk around in a small room. During or just before each of these tasks, participants will receive rTMS. In rTMS, a small plastic coil is placed next to the participant's head. The coil will be placed over the relevant brain region identified during the participant's fMRI scan. The coil will then generate a magnetic pulse, and stimulation will occur. The entire visit will last about one and a half hours.
Study: NCT02441777

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polarization-Sensitive OFDI
Description: OCT Imaging of the eye
Study: NCT06276439

Intervention type: PROCEDURE
Intervention: Surgical removal of breast cancer and lymph nodes
Description: The patients will undergo a surgical procedure to remove tumor tissue in the breast and its associated lymph nodes. No clinical decision is based on the imaging device tested.

Intervention type: PROCEDURE
Intervention: Surgical removal of breast cancer and lymph nodes
Description: The patients will undergo a surgical procedure to remove tumor tissue in the breast and its associated lymph nodes. No clinical decision is based on the imaging device tested.
Study: NCT04673331

Intervention type: OTHER
Intervention: exercise capacity
Description: 3minute step test and 1minute sit to stand test used assessment of exercise capacity.

Intervention type: OTHER
Intervention: exercise capacity
Description: 3minute step test and 1minute sit to stand test used assessment of exercise capacity.
Study: NCT01503281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circuit training
Description: Aerobic and resistance training exercises + Mediterranean diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circuit training
Description: Aerobic and resistance training exercises + Mediterranean diet
Study: NCT06441344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab plus Anlotinib
Description: For patients who did not progress after standard chemotherapy, toripalimab plus anlotinib maintenance therapy was used

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toripalimab
Description: For patients who did not progress after standard chemotherapy+toripalimab, toripalimab maintenance therapy was used
Study: NCT05653661

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scans

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI scans

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel/Danburstotug Complex AP160
Description: Given IV
Study: NCT06505850

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tapered-shaped cuff tracheal tube
Description: Tracheal intubation with a tapered-shaped cuff tube

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cylindrical-shaped cuff tracheal tube
Description: Tracheal intubation with a cylindrical-shaped cuff tube
Study: NCT06565078

Intervention type: DRUG
Intervention: Immune Globulin Subcutaneous (Human), 20% Solution
Description: CUVITRU 20% Solution
Study: NCT05056688

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Testicular Model BSE/TSE Training Set
Description: The investigators will use the Testicular Model BSE/TSE Trainer to transform individuals' routine testicular self-examination into behavior.
Study: NCT06105086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semi-structured interview
Description: Participants will be asked pre-defined questions and are allowed to elaborate on the subject.
Study: NCT05713903

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic right colectomy
Description: Resection of the ascending colon via a laparoscopic approach, adhering to the CME principles

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open right colectomy
Description: Resection of the ascending colon via an open approach, adhering to the CME principles
Study: NCT06441201

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulse flowmeter
Description: Measures peripheral pulse volumes by an electrode applied non-invasively to the lower extremity (left or right) at the beginning of the endoscopic evaluation for the duration of the procedure, and up to 2 hours after the completion of the procedure.
Study: NCT06306651

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula therapy group
Description: Patients who will be randomized to high flow nasal cannula therapy. High flow nasal oxygen cannula will be applied at a flow of 20 L/min at FiO2 of 0.4 at a temperature of 36oC

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional oxygen therapy group
Description: Patients who will be randomized to simple oxygen mask therapy. The simple face mask will be applied in a rate range between 6-10 L/min.
Study: NCT03867786

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will complete an acute exercise visit.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video Control
Description: Participants will complete a video control visit.
Study: NCT06259591

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pedometer follow-up
Description: The daily step count will be obtained from the patients using a pedometer app (OutWalk) from day 8 to day 30 after surgery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedometer follow-up
Description: The daily step count will be obtained from the patients using a pedometer app (OutWalk) from day 8 to day 30 after surgery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ambulation coaching
Description: Patients will receive coaching text messages every Monday, Wednesday and Friday between day 8 and day 30 after surgery, based on a pre-fixed template.
Study: NCT06482762

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BrainSonix Pulsar 1002
Description: Device that delivers low intensity focused ultrasound
Study: NCT06332781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin
Description: administered via bladder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin
Description: administered PO
Study: NCT05813652

Intervention type: OTHER
Intervention: Pre-pandemic time period (Jun 22, 2018 to March 12, 2020)
Description: The primary exposure is the time period of the pandemic (March 13, 2020 to Dec 3, 2021), compared to pre-pandemic (Jun 22, 2018 to pandemic onset March 12, 2020)

Intervention type: OTHER
Intervention: Peri-pandemic time period (March 13, 2020 to December 3, 2021)
Description: The primary exposure is the time period of the pandemic (March 13, 2020 to Dec 3, 2021), compared to pre-pandemic (Jun 22, 2018 to pandemic onset March 12, 2020)
Study: NCT05211921

Intervention type: DEVICE
Group type: OTHER
Intervention: Multi-Gyn ActiGel Plus
Description: vaginal gel
Study: NCT05919381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentuximab Injection
Description: Gentuximab Injection 8 mg/kg, D1, 15 intravenous drip, a cycle every 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gentuximab Injection
Description: Gentuximab Injection 8 mg/kg, D1, 15 intravenous drip, a cycle every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentuximab Injection Placebo
Description: Gentuximab Injection Placebo 8 mg/kg, D1, 15 intravenous drip, a cycle every 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gentuximab Injection Placebo
Description: Gentuximab Injection Placebo 8 mg/kg, D1, 15 intravenous drip, a cycle every 28 days.
Study: NCT05783921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin
Description: TQB2618 injection is an Anti TIM-3 (T-cell immunoglobulin and mucin domain-3) monoclonal antibody.~Penpulimab injection is a humanized Monoclonal Antibody target Programmed Cell Death Protein 1 (PD-1).~Paclitaxel is a anti-microtubule drug, which promotes tubulin polymerization, inhibits depolymerization, maintains tubulin stability and inhibits cell mitosis.~Cisplatin inhibits DNA synthesis by generating in-strand interstrand crosslinking with DNA. Protein and RNA synthesis can also be inhibited.~Carboplatin is a cyclic nonspecific antitumor agents that cause cross-linking between DNA strands and affect their synthesis to inhibit cancer cells.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin
Description: Penpulimab injection is a humanized Monoclonal Antibody target Programmed Cell Death Protein 1 (PD-1).~Paclitaxel is a anti-microtubule drug, which promotes tubulin polymerization, inhibits depolymerization, maintains tubulin stability and inhibits cell mitosis.~Cisplatin inhibits DNA synthesis by generating in-strand interstrand crosslinking with DNA. Protein and RNA synthesis can also be inhibited.~Carboplatin is a cyclic nonspecific antitumor agents that cause cross-linking between DNA strands and affect their synthesis to inhibit cancer cells.
Study: NCT05877794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: central venous catheter insertion
Description: All patients were under trendlenburg position (10 degrees) and disinfected for CVC catheterization. After attaching 2 suture wings of 18G single catheter set to the insertion needle in the 7 Fr or 8 Fr central catheter set, check the IJV to be punctured with an ultrasonic probe. The IJV is punctured using a cross sectional image confirmed at the cricoid cartilage level. After confirming the needle tip on the ultrasound image and blood coming out, the guide wire is mounted on the IJV and then a CVC catheter (arrow international INC) ., USA) is inserted. All actions are performed by a specialist who has more than 30 CVC catheterization experiences using ultrasound, and the occurrence of side effects and the time from puncture to guide wire entry are recorded by another researcher. After the procedure, the researcher who directly performed the procedure records the difficulty or difference compared to when using a conventional needle that does not have a suture wing installed.
Study: NCT06011798

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Anti-VEGF control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Anti-VEGF control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: foselutoclax
Description: Experimental drug
Study: NCT05940545

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Favipiravir
Description: Small molecule antiviral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Favipiravir
Description: Small molecule antiviral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Favipiravir
Description: Small molecule antiviral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Favipiravir
Description: Small molecule antiviral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Small molecule antiviral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Small molecule antiviral
Study: NCT06322368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofunctional and respiratory training program
Description: The patients will receive exercises included in a myofunctional approach and a respiratory training focused on inspiratory and expiratory muscles using a device.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Range of motion and thermal and mechanical stimulation exercising
Description: The patients will receive the standard treatment of speech and language therapy including range of motion exercises (open and close the mouth) and thermal and mechanical stimulation in the orofacial region.
Study: NCT05144880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: A total of 12 treatment sessions will be administered to each participant. The acupoints of needles inserted for each participant in each session are DU20, EX-HN1, DU29, HT17, PC6, RN6, RN4, LR3 and SP6. The needles will be manually stimulated by rotating, thrusting, stirring, etc. to produce ''De Qi'' sensation. Then we will use electroacupuncture for acupoint stimulation lasting 30min. The frequency will be set as 2Hz for the electroacupuncture with 2Hz group and the frequency will be set as 100Hz for the electroacupuncture with 100Hz group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: A total of 12 treatment sessions will be administered to each participant. The acupoints of needles inserted for each participant in each session are DU20, EX-HN1, DU29, HT17, PC6, RN6, RN4, LR3 and SP6. The needles will be manually stimulated by rotating, thrusting, stirring, etc. to produce ''De Qi'' sensation. Then we will use electroacupuncture for acupoint stimulation lasting 30min. The frequency will be set as 2Hz for the electroacupuncture with 2Hz group and the frequency will be set as 100Hz for the electroacupuncture with 100Hz group.
Study: NCT05960305

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1213416
Description: Tobacco Flavor

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1213422
Description: Tobacco Flavor

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1213716
Description: Tobacco Flavor

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1213722
Description: Tobacco Flavor
Study: NCT04895215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-2004
Description: Taken 3 times daily with food
Study: NCT05307952

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tone Audiometry
Description: Evaluation of the participants' audiometrical thresholds

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Spectrotemporal Assessment
Description: Evaluation of the participants' promptness in detecting a modulation of a harmonic complex
Study: NCT04895215

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take 3 times daily with food
Study: NCT05960305

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1211216
Description: Menthol Flavor

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1211222
Description: Menthol Flavor

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1213616
Description: Menthol Flavor

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1213622
Description: Menthol Flavor

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1213816
Description: NTNM Flavor

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1213822
Description: NTNM Flavor

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1211916
Description: NTNM Flavor

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: P1211922
Description: NTNM Flavor
Study: NCT05501574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Inhalation Powder
Description: Tacrolimus powder for inhalation to prevent acute allograft rejection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plastiape RS00 Dry Powder inhaler device
Description: dry powder inhaler device
Study: NCT05923099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 138559
Description: LEO 138559 given by injection just under the skin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 138559
Description: LEO 138559 given by injection just under the skin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 138559
Description: LEO 138559 given by injection just under the skin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 138559
Description: LEO 138559 given by injection just under the skin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given by injection just under the skin
Study: NCT06124612

Intervention type: DIAGNOSTIC_TEST
Intervention: Thrombotic assessment
Description: GTT~The Global Thrombosis Test (GTT) (Thromboquest Limited, UK) is an in vitro method imitating high shear stress conditions akin to that which exist in a severely stenosed artery. The test measures platelet reactivity (occlusion time) and endogenous fibrinolysis time (lysis time).~TEG Thromboelastography (TEG, Haemonetics Corporation, USA) is a technique that assesses the whole process of clotting and its viscoelastic properties, from the initial activation and aggregation of platelets, to the role of thrombin and finally the stability of the formed clot, as a measure of fibrinolytic resistance.~Citrated plasma will be stored for subsequent evaluation of thrombosis and fibrinolysis markers (including but not restricted to D-dimer, PAI-1, hs-CRP, NETs)
Study: NCT05219084

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hip denervation
Description: Lidocaine 2% 2ml was injected into each genicular nerve

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intra-articular hydration
Description: 10 ml; of normal; saline were injected inside the hip joint

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined group
Description: hip denervation and intra-articular hydration were conducted together
Study: NCT05307952

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Phoneme and Speech Perception
Description: Evaluation of the participants' understanding of phonemes and short words, both in quiet and in noise

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Digit Triplet Test
Description: Evaluation of the participants' ability to discern speech in noise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized fitting
Description: Adjustment of the parameters of the participants' cochlear implants aimed at improving their speech perception

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized training
Description: Self-administered training exercises focused on the speech components the participants are experiencing difficulties into